Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-29 @ 7:13 AM
Study NCT ID:
NCT04007835
Status:
UNKNOWN
Last Update Posted:
2019-07-05
First Post:
2019-06-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Sponsor:
Guangdong Association of Clinical Trials
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CTONG1803
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |